Cannabis Products Gain Popularity Domestically and Globally

Monday, February 27, 2017 Drug News
Email Print This Page Comment
Font : A-A+

NEW YORK, February 27, 2017 /PRNewswire/ --

A recent research report published by Grand View Research, Inc. indicates

that the global medical marijuana market alone is expected to reach a value of $55.8 billion by 2025. Earlier in 2016, Washington D.C. along with 28 states have legalized marijuana for medical
uses. In 2016, states such as Arkansas, Florida, North Dakota, Ohio and Pennsylvania were approved to use the drug in medical applications such as chemotherapies and pain management. The growing number of states and countries getting approval for using it in therapeutic applications is one of the crucial factors driving the demand over the coming few years. ChineseInvestors.com Inc. (OTC: CIIX), Terra Tech Corporation (OTC: TRTC), Canopy Growth Corporation (OTC: TWMJF), Cannabis Sativa Inc. (OTC: CBDS), United Cannabis Corporation (OTC: CNAB)

The rapidly growing number of cannabis legalization in the U.S. is one of the key attributes for its increased demand in therapeutic and recreational uses. Regulated cannabis sales in North America totaled $6.9 billion in 2016, a 30 percent increase from 2015. Sales are projected to increase to $21.6 billion by the year 2021 representing a 26 percent compound annual growth rate, according to a report by Arcview Market Research.

ChineseInvestors.com Inc. (OTCQB: CIIX) just announced this morning that the company's CEO Warren Wang attended Shangdong Yibao Biologics Co. Ltd.'s annual conference, and, by invitation, delivered a five-minute speech to celebrate the 18th anniversary of Yibao Biologics.

Yibao Biologics is a modern high-tech enterprise which specializes in the research, production and sales of chondroitin sulfate series and Confucian series health care products. The company is also the largest and most professional manufacturer of chondroitin sulfate in the world. Yibao Biologics invited ChineseInvestors.com to participate in its annual direct sales conference to discuss the development and prospects of Chinese health products enterprises in the United States.

As an attendee of the conference, Wang learned how direct sales of the health products industry operate in China, and how to apply this information to build the sales team of CIIX's ChineseCBDoil.com retail website. "The market for direct selling of natural products in the United States has considerable depth, and varies from the Chinese market in many ways. It was an honor to attend this year's Yibao Biologics conference, where I was able to gain valuable market insight as well as present my own expertise to fellow attendees," says Wang.

ChineseInvestors.com recently launched http://www.ChineseCBDoil.com, marking the company's official entry into the CBD hemp oil markets.

"ChineseInvestors.com will continue to sell CBD health products through online retailing methods; we will gradually open offline selling channels and combine word-of-mouth marketing with Internet retailing. Our goal is to benefit more Chinese people with reliable logistics network and commodity channels, as well as to provide leading positions in products and resources. Due to the huge size of the Chinese direct selling market, we hope to further expand our market share through investment and alliance in and with direct selling companies," concludes Wang.

Terra Tech Corporation (OTCQX: TRTC) operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Garden, MediFarm LLC and GrowOp Technology. Blüm's retail medical cannabis facilities focus on providing the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions. Blüm offers a broad selection of medical cannabis products including; flowers, concentrates and edibles through Oakland and multiple Nevada locations. IVXX, Inc. is a wholly-owned subsidiary of Terra Tech that produces medical cannabis-extracted products for regulated medical cannabis dispensaries throughout California. The Company's wholly-owned subsidiary, Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores. MediFarm LLC subsidiaries are focused on medical cannabis cultivation and permitting businesses throughout Nevada. The Company's wholly-owned subsidiary GrowOp Technology, specializes in controlled environment agricultural technologies.

Canopy Growth Corporation (OTC: TWMJF) subsidiary, Bedrocan®, pioneered medical cannabis in Holland through decades of selection and refinement, leading to standardized, whole bud cannabis strains. Bedrocan Canada supplies the same standardized strains to the Canadian market through exclusive licensing rights to the American continents, an arrangement it will also enjoy for all future genetic advancements. Due to its consistency over time, Bedrocan's strains have been used in clinical research in seven European countries. That commitment to research didn't stay on the east side of the Atlantic - Bedrocan Canada recently launched one of the largest clinical cannabis studies in the world, the EQUAL Study, to evaluate quality of life before and after medical cannabis use.

Cannabis Sativa Inc. (OTCQB: CBDS) announced that the new Ibudtender app will be ready for beta testing. This new app will hold the highest health and safety standards for consumers to date. "The Ibudtender team has been working hard to complete what will be the most sophisticated app in the space," said David Tobias, President of Cannabis Sativa. "The beta test will give the technology a chance to perform, interact with users, get analyzed and perfected, and a final release to follow quickly." Cannabis Sativa Inc. develops and promotes natural cannabis products.

United Cannabis Corporation (OTCQB: CNAB) has signed an exclusive licensing agreement with Vessel Life Sciences to produce and distribute its products, including the award-winning Prana Bio Nutrient Medicinals, throughout Pennsylvania. Vessel Life Science LLC is dedicated to advancing the use of cannabinoids in medicine, with a focus on the refinement of genetics for medical grade strains of CBD-rich cannabis plants for the commonwealth of Pennsylvania's patient base. Founded on the principles of patient-driven results, VLS' mission is to offer the highest quality of products that indisputably prove and reinforce the use of medical marijuana for patient benefits and health advances.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com expects to be compensated five thousand dollars for financial news dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information: Media Contact: info@financialbuzz.com +1-877-601-1879

URL: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook